NEW YORK, Jan. 18 (GenomeWeb News) - Cambrex subsidiary Cambrex Bio Science Wokingham will buy conditionally immortalized cell lines and related intellectual property and equipment from British biotech Xcellsyz, Cambrex said today.
Financial terms of the deal were not disclosed.
Last week, Cambrex signed a worldwide licensing pact with Geron that will see it develop its own immortalized cell lines for distribution using Geron's human telomerase reverse transcriptase technology. XCellsyz last year had signed a similar agreement for Geron's telomerase technology, which it used to develop its own immortalized cell lines.
Cambrex said it will use the recently acquired technologies to immortalize a broad set of cell types, which it will sell to researchers for a variety of applications, including cell-based high-throughput drug screening and toxicity testing.